1. Home
  2. GLTO vs ELOG Comparison

GLTO vs ELOG Comparison

Compare GLTO & ELOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$28.83

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

ELOG

Eastern International Ltd. Ordinary Shares

N/A

Current Price

$1.25

Market Cap

14.2M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
GLTO
ELOG
Founded
2011
2006
Country
Denmark
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Integrated Freight & Logistics
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
14.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
GLTO
ELOG
Price
$28.83
$1.25
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$43.67
N/A
AVG Volume (30 Days)
314.6K
42.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$6.84
Revenue Growth
N/A
N/A
52 Week Low
$2.01
$0.80
52 Week High
$38.33
$3.07

Technical Indicators

Market Signals
Indicator
GLTO
ELOG
Relative Strength Index (RSI) 52.24 53.03
Support Level $24.53 $0.86
Resistance Level $32.86 $1.60
Average True Range (ATR) 2.99 0.17
MACD -0.02 0.03
Stochastic Oscillator 62.69 80.36

Price Performance

Historical Comparison
GLTO
ELOG

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

About ELOG Eastern International Ltd. Ordinary Shares

Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.

Share on Social Networks: